CTIS2024-514688-24-00招募中1 期
Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML - FLAMSAClax
Heinrich-Heine-Universitaet Duesseldorf0 个研究点目标入组 38 人开始时间: 2024年7月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •MDS, CMML or sAML according to WHO classification (revised version 2016) with a marrow blast count >5% and/or high-risk genetic features (eg. bad risk karyotype according to the IPSS-R / ELN classification or presence of unfavorable somatic mutations (e.g. TP53, RUNX1, IDH1, IDH2, KMT2A, DEK-NUP214 or RAS pathway mutations including NRAS, KRAS, PTPN11, CBL, NF1, RIT1 or KIT), falling into the high or very high risk category of the IPSS-R or IPSS M) any time between diagnosis and inclusion.
排除标准
- •previous cytotoxic therapy exceeding oral Hydroxyurea or >2 courses of treatment with Azacytidine, Decitabine or low dose Ara-C alone or in combination with Venetoclax
研究者
相似试验
招募中
2 期
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leukemia undergoing allogeneic blood stem cell transplantation2024-514688-24-00Heinrich-Heine-Universitaet Duesseldorf38
进行中（未招募）
1 期
Trial to evaluate the safety and efficacy of a new drug in combination with the standard therapy to prevent the rejection which could occur after a transplantation.Adult patiens after allogeneic stem cell transplantationMedDRA version: 19.1Level: LLTClassification code 10018653Term: Graft-versus-host disease <GVHD>System Organ Class: 100000004870MedDRA version: 19.1Level: LLTClassification code 10067859Term: Allogenic stem cell transplantationSystem Organ Class: 100000004865EUCTR2016-002503-26-ESFundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)152
尚未招募
1 期
CIGB-Mambisa/Abdala in convalescentsCOVID-19 ConvalescenceCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000382Center for Genetic Engineering and Biotechnology (CIGB)120
进行中（未招募）
1 期
Safety assessment and dose of fibrin sealant derived from snake venom in the treatment of wounds.RBR-9mbdj3Faculdade de Medicina de Botucatu - Unesp
招募中
1 期
Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patientsCastration resistant prostate cancerJPRN-UMIN000006142Department of Urology, Osaka University Graduate School of Medicine12